PAR 0.00% 19.5¢ paradigm biopharmaceuticals limited..

Where we at?, page-358

  1. 384 Posts.
    lightbulb Created with Sketch. 58
    the chapter 11 allows Endo to restructure there business is how I read it,could well be a great opportunity for Endo to be involved with a non opioid based treatment who knows.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.